Pharmaceutical intelligence for Biohaven Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJune 30, 2026

Biohaven's BHV-1300 Trial for Graves' Disease Underway

Biohaven Therapeutics is conducting a trial to assess the efficacy and safety of BHV-1300 in adults with Graves' disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJune 30, 2026

Biohaven's BHV-1300 Trial for Graves' Disease Underway

Biohaven Therapeutics is conducting a trial to assess the efficacy and safety of BHV-1300 in adults with Graves' disease.

Competitive activity

No signals indexed for this entity yet.

Assets

BHV-1300 →

Therapeutic areas

Endocrinology →

Graves' Disease →

Indications

Graves' Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.